Human T cell lymphotropic virus: necessity for and feasibility of a vaccine - PubMed (original) (raw)
Review
. 1994:187:47-55; discussion 55-60.
doi: 10.1002/9780470514672.ch4.
Affiliations
- PMID: 7796676
- DOI: 10.1002/9780470514672.ch4
Review
Human T cell lymphotropic virus: necessity for and feasibility of a vaccine
G de Thé et al. Ciba Found Symp. 1994.
Abstract
Human T cell lymphotropic virus types I and II (HTLV-I/II) are endemic in certain areas of the world. They cause two life-threatening diseases, adult T cell leukaemia/lymphoma and tropical spastic paraparesis. A vaccine is needed because in developing countries there are no other feasible preventive interventions against these diseases and in Western countries intravenous drug users at high risk for HTLV-I and HTLV-II infections and the health workers in contact with such populations must be protected. We have developed a rat model in which we observed variations of susceptibility to viral infection between inbred strains, the most susceptible being the Fischer F344, and the possibility of viral latency in the nervous system. We have prepared a recombinant adenovirus vector that expresses the HTLV-I envelope glycoprotein env in HeLa cells. A target human population in French Guyana, in which the prevalence rate reaches 5.6% in one ethnic group (Bonis), has been identified for possible intervention.
Similar articles
- An HTLV-I/II vaccine: from animal models to clinical trials?
de Thé G, Kazanji M. de Thé G, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S191-8. doi: 10.1097/00042560-199600001-00029. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8797723 Review. - Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects.
Bomford R, Kazanji M, De Thé G. Bomford R, et al. AIDS Res Hum Retroviruses. 1996 Mar 20;12(5):403-5. doi: 10.1089/aid.1996.12.403. AIDS Res Hum Retroviruses. 1996. PMID: 8882319 Review. No abstract available. - [Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires].
Blejer JL, Saguier MC, Salamone HJ, Carreras LA. Blejer JL, et al. Sangre (Barc). 1995 Dec;40(6):447-51. Sangre (Barc). 1995. PMID: 8850226 Spanish. - An HTLV-I vaccine: why, how, for whom?
de Thé G, Bomford R. de Thé G, et al. AIDS Res Hum Retroviruses. 1993 May;9(5):381-6. doi: 10.1089/aid.1993.9.381. AIDS Res Hum Retroviruses. 1993. PMID: 8318266 Review. - Human T-cell lymphotropic virus type I and II in transfusion medicine.
Sandler SG, Fang CT, Williams AE. Sandler SG, et al. Transfus Med Rev. 1991 Apr;5(2):93-107. doi: 10.1016/s0887-7963(91)70197-1. Transfus Med Rev. 1991. PMID: 1687974 Review.
Cited by
- Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Carroll MW, et al. Vaccine. 1997 Mar;15(4):387-94. doi: 10.1016/s0264-410x(96)00195-8. Vaccine. 1997. PMID: 9141209 Free PMC article.